PPT-Bimekizumab efficacy and safety versus secukinumab in patients with moderate-to-severe PowerPoint Presentation

Reich K et al Methods Patients with moderatetosevere plaque psoriasis were randomized 11 to Bimekizumab 320 mg every 4 weeks S ecukinumab 300 mg every 4 weeks after

Upload by edolie
Published on 2023-07-27

Presentation Embed Code

<iframe width="560" height="315" src="https://www.docslides.com/embed/1011811" frameborder="0" allowfullscreen></iframe>

Download Presentation

Download Presentation The PPT/PDF document "Bimekizumab efficacy and safety versus s..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.